ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Single-cell peripheral immunoprofiling of lewy body andÌýParkinson's disease in a multi-site cohort.

ÌÇÐÄ´«Ã½

Single-cell peripheral immunoprofiling of lewy body and Parkinson's disease in a multi-site cohort. Molecular neurodegeneration Phongpreecha, T., Mathi, K., Cholerton, B., Fox, E. J., Sigal, N., Espinosa, C., Reincke, M., Chung, P., Hwang, L. J., Gajera, C. R., Berson, E., Perna, A., Xie, F., Shu, C. H., Hazra, D., Channappa, D., Dunn, J. E., Kipp, L. B., Poston, K. L., Montine, K. S., Maecker, H. T., Aghaeepour, N., Montine, T. J. 2024; 19 (1): 59

Abstract

Multiple lines of evidence support peripheral organs in the initiation or progression of Lewy body disease (LBD), a spectrum of neurodegenerative diagnoses that include Parkinson's Disease (PD) without or with dementia (PDD) and dementia with Lewy bodies (DLB). However, the potential contribution of the peripheral immune response to LBD remains unclear. This study aims to characterize peripheral immune responses unique to participants with LBD at single-cell resolution to highlight potential biomarkers and increase mechanistic understanding of LBD pathogenesis in humans.In a case-control study, peripheral mononuclear cell (PBMC) samples from ÌÇÐÄ´«Ã½ participants were randomly sampled from multiple sites across the United States. The diagnosis groups comprise healthy controls (HC, n?=?159), LBD (n?=?110), Alzheimer's disease dementia (ADD, n?=?97), other neurodegenerative disease controls (NDC, n?=?19), and immune disease controls (IDC, n?=?14). PBMCs were activated with three stimulants (LPS, IL-6, and IFNa) or remained at basal state, stained by 13 surface markers and 7 intracellular signal markers, and analyzed by flow cytometry, which generated 1,184 immune features after gating.The model classified LBD from HC with an AUROC of 0.87?±?0.06 and AUPRC of 0.80?±?0.06. Without retraining, the same model was able to distinguish LBD from ADD, NDC, and IDC. Model predictions were driven by pPLC?2, p38, and pSTAT5 signals from specific cell populations under specific activation. The immune responses characteristic for LBD were not associated with other common medical conditions related to the risk of LBD or dementia, such as sleep disorders, hypertension, or diabetes.Quantification of PBMC immune response from multisite ÌÇÐÄ´«Ã½ participants yielded a unique pattern for LBD compared to HC, multiple related neurodegenerative diseases, and autoimmune diseases thereby highlighting potential biomarkers and mechanisms of disease.

View details for

View details for

View details for